Adjuvant therapy for lung neuroendocrine neoplasms

作     者：Robert A Ramirez Katharine Thomas Aasems Jacob Karen Lin Yvette Bren-Mattison Aman Chauhan 

作者机构：Department of Medicine-Division of Hematology/OncologyVanderbilt University Medical CenterNashvilleTN 37232United States Department of Hematology and OncologyLouisiana State University Health Sciences CenterNew OrleansLA 70112United States Division of Medical OncologyUniversity of KentuckyLexingtonKY 40536United States Department of OncologyBrookwood Baptist HealthBirminghamAL 35209United States Department of SurgeryLouisiana State University Health Sciences CenterNew OrleansLA 70112United States New Orleans Louisiana Neuroendocrine Tumor Specialists(NOLANETS)Ochsner Medical CenterKennerLA 70065United States 

出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)

年 卷 期：2021年第12卷第8期

页      面：664-674页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Neuroendocrine Adjuvant therapy Lung Pulmonary carcinoid Small cell lung cancer 

摘      要：Pulmonary neuroendocrine neoplasms(NENs)represent a minority of lung cancers and vary from slower growing pulmonary carcinoid(PC)tumors to aggressive small cell lung cancer(SCLC).While SCLC can account for up to 15%of lung cancer,PCs are uncommon and represent about 2%of lung *** resection is the standard of care for early-stage PCs and should also be considered in early stage large cell neuroendocrine carcinoma(LCNEC)and *** treatment is generally accepted for aggressive LCNEC and SCLC,however,less well established for *** admit a lack of trials to support a high-level recommendation for adjuvant *** manuscript will discuss the role for adjuvant therapy in NENs and review the available literature.